N-[(7S)-1-((ethyl)carbonyloxy)-2,3,10-trimethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl]acetamide | 1057403-90-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 英文名称: N-[(7S)-1-((ethyl)carbonyloxy)-2,3,10-trimethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl]acetamide
• 英文别名: [(7S)-7-acetamido-2,3,10-trimethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-1-yl] propanoate
• CAS: 1057403-90-3
• 化学式: C₂₄H₂₇NO₇
• 分子量: 441.481
• InChiKey: XWTZXJUWZQSHIH-KRWDZBQOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  32
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  100
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  秋水仙碱 在 四氯化锡 、 sodium hydroxide 作用下， 以 水 、 丙酮 为溶剂， 反应 15.0h， 生成 N-[(7S)-1-((ethyl)carbonyloxy)-2,3,10-trimethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl]acetamide
  参考文献：
  名称：

  [EN] NOVEL COLCHICINE DERIVATIVES, METHODS AND USES THEREOF
  [FR] NOUVEAUX DÉRIVÉS DE COLCHICINE, LEURS PROCÉDÉS ET UTILISATIONS

  摘要：

  本发明涉及秋水仙碱衍生物、其制备方法及其用于治疗癌症的应用。在某些实施例中，秋水仙碱衍生物包括公式(I)的化合物，其中Z是O或S；R1选自H、卤素基团、取代或不取代的烃基团或取代或不取代的杂原子基团；R2和R3各自独立地选自H、卤素基团、取代或不取代的烃基团、取代或不取代的杂原子基团、取代或不取代的碳环基团、取代或不取代的杂环基团、取代或不取代的芳香基团或取代或不取代的杂芳香基团；R选自H或取代或不取代的烃基团，但R、R2和R3为甲基基团时，R1不是-COCH3。

  公开号：

  WO2011022805A1

文献信息

• WO2020000109A5
  申请人：——

  公开号：WO2020000109A5

  公开（公告）日：2022-06-22
• The efficacy of new colchicine derivatives and viability of the T-Lymphoblastoid cells in three-dimensional culture using 19F MRI and HPLC-UV ex vivo
  作者：Dorota Bartusik、Boguslaw Tomanek、Erika Lattová、Hélène Perreault、Jack Tuszynski、Gino Fallone

  DOI：10.1016/j.bioorg.2009.07.007

  日期：2009.12

  The paper describes ex vivo applications of colchicine derivatives for the treatment of human T-Lymphoblastoid (CEM) cells. Moreover, the role of the substitutions of ring A at C-1 and C-7 side chain of colchicine analogues was probed by the synthesis and examination of their effects on the three-dimensional (3-D) CEM cells' growth. The CEM cells were cultured in the hollow fiber bioreactor (HFB) device. We used H-1 and F-19 magnetic resonance imaging (MRI) to monitor changes in 3-D CEM cell culture. F-19 MRI was used for visualization of the cellular uptake of new fluorine derivatives. Before and after treatment CEM cells profile was investigated with high performance liquid chromatography (HPLC-UV). Crown Copyright (C) 2009 Published by Elsevier Inc. All rights reserved.
• [EN] NOVEL COLCHICINE DERIVATIVES, METHODS AND USES THEREOF<br/>[FR] NOUVEAUX DÉRIVÉS DE COLCHICINE, LEURS PROCÉDÉS ET UTILISATIONS
  申请人：ALBERTA HEALTH SERVICES

  公开号：WO2011022805A1

  公开（公告）日：2011-03-03

  The invention relates to colchicine derivatives, methods and uses thereof for treatment of cancer. In certain embodiments, the colchicine derivative comprises a compound of formula (I), wherein Z is O or S; R1 is selected fro H, a halo group, a substituted or unsubstituted hydrocarbon group, or a substituted or unsubstituted heterogeneous group; R2 and R3 are each independently selected from H, a halo group, a substituted or unsubstituted hydrocarbon group, a substituted or unsubstituted heterogeneous group, a substituted or unsubstituted carbocyclic group, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aromatic, or a substituted or unsubstituted heteroaromatic; R is selected from H or a substituted or unsubstituted hydrocarbon group, with the proviso that when R, R2 and R3 are methyl groups, R1 is not -COCH3.

  本发明涉及秋水仙碱衍生物、其制备方法及其用于治疗癌症的应用。在某些实施例中，秋水仙碱衍生物包括公式(I)的化合物，其中Z是O或S；R1选自H、卤素基团、取代或不取代的烃基团或取代或不取代的杂原子基团；R2和R3各自独立地选自H、卤素基团、取代或不取代的烃基团、取代或不取代的杂原子基团、取代或不取代的碳环基团、取代或不取代的杂环基团、取代或不取代的芳香基团或取代或不取代的杂芳香基团；R选自H或取代或不取代的烃基团，但R、R2和R3为甲基基团时，R1不是-COCH3。